Literature DB >> 17613435

Recruitment of RXR by homotetrameric RARalpha fusion proteins is essential for transformation.

Bernd B Zeisig1, Colin Kwok, Arthur Zelent, Pattabhiraman Shankaranarayanan, Hinrich Gronemeyer, Shuo Dong, Chi Wai Eric So.   

Abstract

While formation of higher-order oncogenic transcriptional complexes is critical for RARalpha fusion proteins in acute promyelocytic leukemia, the essential components and their roles in mediating transformation are still largely unknown. To this end, the present study demonstrates that homodimerization is not sufficient for RARalpha fusion-mediated transformation, which requires higher-order homotetramerization. Surprisingly, intrinsic homo-oligomeric DNA binding by the fusion proteins is also dispensable. Importantly, higher-order RXR/RARalpha fusion hetero-oligomeric complexes that aberrantly recruit transcriptional corepressors to downstream targets are essential for transformation. Intervention of RXR-dependent pathways by panRXR-agonists or RXRalpha shRNAs suppresses RARalpha fusion-mediated transformation. Taken together, these results define the oncogenic threshold for self-association and reveal the pathological significance of higher-order RARalpha fusion/RXR hetero-oligomeric complexes and their potential value as a therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17613435     DOI: 10.1016/j.ccr.2007.06.006

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  29 in total

1.  Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.

Authors:  Rihab Nasr; Hugues de Thé
Journal:  Int J Hematol       Date:  2010-05-11       Impact factor: 2.490

Review 2.  The retinoid X receptors and their ligands.

Authors:  Marcia I Dawson; Zebin Xia
Journal:  Biochim Biophys Acta       Date:  2011-10-01

Review 3.  Retinoid pathway and cancer therapeutics.

Authors:  Nathan Bushue; Yu-Jui Yvonne Wan
Journal:  Adv Drug Deliv Rev       Date:  2010-08-03       Impact factor: 15.470

4.  Aberrant chromatin remodeling by retinoic acid receptor alpha fusion proteins assessed at the single-cell level.

Authors:  Jihui Qiu; Ying Huang; Guoqiang Chen; Zhu Chen; David J Tweardy; Shuo Dong
Journal:  Mol Biol Cell       Date:  2007-08-01       Impact factor: 4.138

5.  Modulators of the structural dynamics of the retinoid X receptor to reveal receptor function.

Authors:  Virginie Nahoum; Efrén Pérez; Pierre Germain; Fátima Rodríguez-Barrios; Fabio Manzo; Sabrina Kammerer; Geraldine Lemaire; Oliver Hirsch; Catherine A Royer; Hinrich Gronemeyer; Angel R de Lera; William Bourguet
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-18       Impact factor: 11.205

6.  Inhibition of miR-193a expression by Max and RXRα activates K-Ras and PLAU to mediate distinct aspects of cellular transformation.

Authors:  Dimitrios Iliopoulos; Asaf Rotem; Kevin Struhl
Journal:  Cancer Res       Date:  2011-06-13       Impact factor: 12.701

7.  NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling.

Authors:  Hu Zhou; Wen Liu; Ying Su; Zhen Wei; Jie Liu; Siva Kumar Kolluri; Hua Wu; Yu Cao; Jiebo Chen; Yin Wu; Tingdong Yan; Xihua Cao; Weiwei Gao; Andrei Molotkov; Fuquan Jiang; Wen-Gang Li; Bingzhen Lin; Hai-Ping Zhang; Jinghua Yu; Shi-Peng Luo; Jin-Zhang Zeng; Gregg Duester; Pei-Qiang Huang; Xiao-Kun Zhang
Journal:  Cancer Cell       Date:  2010-06-15       Impact factor: 31.743

Review 8.  DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance.

Authors:  Maria Teresa Esposito; Chi Wai Eric So
Journal:  Chromosoma       Date:  2014-08-12       Impact factor: 4.316

Review 9.  Targeting truncated RXRα for cancer therapy.

Authors:  Xiaokun Zhang; Hu Zhou; Ying Su
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2015-10-21       Impact factor: 3.848

10.  Targeting truncated retinoid X receptor-α by CF31 induces TNF-α-dependent apoptosis.

Authors:  Guang-Hui Wang; Fu-Quan Jiang; Ying-Hui Duan; Zhi-Ping Zeng; Fan Chen; Yi Dai; Jie-Bo Chen; Jin-Xing Liu; Jie Liu; Hu Zhou; Hai-Feng Chen; Jin-Zhang Zeng; Ying Su; Xin-Sheng Yao; Xiao-Kun Zhang
Journal:  Cancer Res       Date:  2012-11-14       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.